What is adjuvant therapy and why is it given after surgery
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Understanding Adjuvant Therapy
What Is Adjuvant Therapy?
Adjuvant therapy is additional cancer treatment given after surgery to help reduce the risk that cancer will return. The word "adjuvant" means "to help" or "to assist"—it works alongside surgery to provide extra protection.
Think of it this way: surgery removes the tumor you can see, but adjuvant therapy targets cancer cells that may have spread beyond the surgical area but are too small to detect with current imaging or blood tests.
Why Doctors Give Adjuvant Therapy
The Clinical Reasoning:
Oncologists use adjuvant therapy because:
-
Microscopic disease may remain - Even after successful surgery, tiny cancer cells (called micrometastases) may have traveled to other parts of your body but aren't visible on scans yet
-
It improves survival outcomes - According to NCCN Guidelines and ASCO recommendations, adjuvant therapy has been shown to reduce recurrence rates and improve long-term survival for many cancer types
-
It's based on risk assessment - Your doctor evaluates factors like:
- Tumor size and stage
- Grade (how aggressive the cancer looks)
- Biomarkers (genetic characteristics of your cancer)
- Whether lymph nodes were involved
- Your overall health
Common Types of Adjuvant Therapy
- Chemotherapy - drugs that kill rapidly dividing cells
- Radiation therapy - targeted energy to kill remaining cancer cells in a specific area
- Hormone therapy - blocks hormones that fuel certain cancers (like breast cancer)
- Targeted therapy - drugs that attack specific mutations in cancer cells
- Immunotherapy - helps your immune system recognize and fight cancer
The Decision-Making Process
Your oncologist will determine whether adjuvant therapy is right for your specific situation by considering your complete medical picture, pathology results, and individual risk factors. Not every patient needs adjuvant therapy—it depends on the type and stage of cancer and other clinical factors.
Questions to ask your care team:
- Based on my pathology results and stage, do I need adjuvant therapy?
- What are the benefits and potential side effects of the recommended treatment?
- How long will treatment last, and what will the schedule look like?
- Are there any clinical trials I should consider?
- How will we monitor for side effects and effectiveness?
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with treatment for cancer patients
Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2
It is h3k27 altered dmg h3k27m negative, egfr a289v myc tp53 mgmt methylated
Your tumor has specific genetic changes H3K27, EGFR, MYC, TP53, MGMT that your doctors will use to guide treatment decisions—these findings help deter